Talaris Therapeutics : Costs Associated with Exit/Disposal - Form 8-K

8-K


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549



FORM 8-K



CURRENT REPORT


Pursuant to... | April 14, 2023

Related Keywords

Delaware ,United States ,Massachusetts ,Washington ,Worcester ,Scott Requadt ,Mary Kay Fenton ,Andrew Farnsworth ,Nancy Krieger ,Michael Zdanowski ,Talaris Therapeutics Inc ,Company Board Of Directors ,Company Annual Report On Form ,Exchange Commission ,Securities Exchange ,Commission File Number ,Securities Exchange Act ,Its Charter ,Principal Executive Offices ,Zip Code ,Telephone Number ,Including Area Code ,Former Name ,Former Address ,Changed Since Last Report ,Securities Act ,Exchange Act ,Talaris Therapeutics ,April Reduction ,Certain Officers ,Compensatory Arrangements ,Chief Executive Officer ,Chief Medical Officer ,Chief Technology Officer ,Chief Human Resources Officer ,Restated Executive Severance ,Control Plan ,Annual Report ,Chief Financial Officer ,Retention Agreement ,Strategic Transaction ,Mary Kay ,Page Interactive Data File ,Current Report ,Private Securities Litigation Reform Act ,Chief Executive ,Nc Stock Exchange ,News ,Information ,Press Release ,United ,Securities ,End ,Exchange ,Form ,Current ,Ursuant Tals Us87410c1045 ,